本文選題：前列腺癌　切入點(diǎn)：細(xì)胞自噬　出處：《安徽醫(yī)科大學(xué)》2015年碩士論文　論文類型：學(xué)位論文

【摘要】：細(xì)胞自噬(Autophagy)是一個(gè)廣泛存在于真核細(xì)胞中的重要的生理過程,主要方式為細(xì)胞初級(jí)溶酶體處理內(nèi)源性底物,包括細(xì)胞清除廢物、重建結(jié)構(gòu)以及生長發(fā)育。生命體借此維持蛋白代謝平衡及細(xì)胞內(nèi)環(huán)境穩(wěn)定,并與疾病的發(fā)生密切相關(guān)。目前,學(xué)術(shù)界公認(rèn)的自噬主要形式有:巨自噬(macroautophagy),微自噬(microautophagy),以及分子伴侶介導(dǎo)的自噬(chaperone mediated autophagy,CMA)。巨自噬即是我們通常所稱的自噬。目前已知的自噬調(diào)控途徑有:Beclin-1信號(hào)途徑;mTOR(Mammalian Target of Rapamycin)信號(hào)途徑;自噬相關(guān)基因(Autophagy Related Gene,Atg)與泛素樣結(jié)合系統(tǒng)(Ubiquitin-link system)。其中,自噬基因Beclin-1與酵母自噬基因Atg6同源,位于染色體17q21,定位于高爾基體參與哺乳動(dòng)物自噬體的形成,是介導(dǎo)其他自噬蛋白定位于前自噬小體的關(guān)鍵因子。前列腺癌(Prostate Cancer,PCa)是當(dāng)今社會(huì)常見的男性惡性腫瘤。近年來,其發(fā)病率在我國男性人群中呈逐年攀高趨勢(shì)。晚期前列腺癌的治療大多依賴于去除雄激素方法。然而,絕大多數(shù)患者最終會(huì)轉(zhuǎn)變?yōu)樾奂に氐挚剐颓傲邢侔?Castrate-Resistant Prostate Cancer,CRPC),導(dǎo)致對(duì)傳統(tǒng)的去勢(shì)治療反應(yīng)效果不佳。相關(guān)研究已經(jīng)初步證明自噬在CRPC中扮演著重要角色,而自噬基因Beclin-1在多種腫瘤組織中呈低水平表達(dá),預(yù)示著細(xì)胞自噬在前列腺癌的發(fā)生、發(fā)展、轉(zhuǎn)歸中發(fā)揮著作用。本課題采用免疫組化的方法檢測(cè)Beclin-1在前列腺癌組織中的表達(dá)并探討其與相關(guān)臨床、病理因素的關(guān)系。本研究取用經(jīng)直腸前列腺穿刺活檢術(shù)后的病理標(biāo)本,共132例,所有標(biāo)本均經(jīng)病理證實(shí)為前列腺腺癌。本研究實(shí)驗(yàn)組即為前列腺腺癌組織,對(duì)照組即為良性前列腺增生組織。納入研究的每例標(biāo)本均至少有一針為良性前列腺增生組織(即癌旁組織)。對(duì)132例患者的全部穿刺標(biāo)本行免疫組化染色,若其中有任何一針染色呈陽性表達(dá),即可納入相應(yīng)的陽性組;若全部為陰性表達(dá),則納入相應(yīng)的陰性組。采用免疫組化Super Vision兩步法檢測(cè)132例前列腺癌組織及癌旁組織中Beclin-1的表達(dá),并分析其與相關(guān)臨床因素的關(guān)系。結(jié)果發(fā)現(xiàn):1.Beclin-1染色陽性物質(zhì)呈棕黃色,表達(dá)位于細(xì)胞漿。在132例前列腺穿刺活檢的病理組織中,癌旁組織的Beclin-1陽性表達(dá)率為54.5%,腫瘤組織的Beclin-1陽性表達(dá)率為38.6%,明顯低于其在癌旁組織中的表達(dá)。2.本研究將132例前列腺癌穿刺標(biāo)本按術(shù)后Gleason評(píng)分不同分為三組:2~4分;5~7分;8分以上。Beclin-1在三組中的陽性表達(dá)率分別為66.7%,39.7%,27.3%,評(píng)分越高,表達(dá)率越低,組間差異具有統(tǒng)計(jì)學(xué)意義。3.Beclin-1的表達(dá)差異與是否發(fā)生淋巴結(jié)轉(zhuǎn)移、是否發(fā)生骨轉(zhuǎn)移有關(guān),具有統(tǒng)計(jì)學(xué)意義(P0.05);而與年齡、是否具有家族史及前列腺炎病史差異均無統(tǒng)計(jì)學(xué)意義(P0.05)。4.在全部132例前列腺癌患者中,有76例進(jìn)行了根治性前列腺切除術(shù),術(shù)后三個(gè)月進(jìn)行隨訪,檢測(cè)PSA水平,有10例≥0.02ng/ml,66例0.02ng/ml。在PSA0.02ng/ml的66例中有42例Beclin-1表達(dá)陽性,陽性率為63.6%,而在PSA≥0.02ng/ml的10例中,2例Beclin-1表達(dá)為陽性,陽性率為20%,明顯低于前者(P0.05)。以上研究提示,自噬基因Beclin-1在前列腺癌組織中表達(dá)下調(diào),并與淋巴結(jié)轉(zhuǎn)移、骨轉(zhuǎn)移及生化復(fù)發(fā)有關(guān),其表達(dá)下調(diào)可能參與前列腺癌的發(fā)生、發(fā)展,為前列腺癌的診斷及治療提供了新的思路。
[Abstract]:Autophagy (Autophagy) is a widespread important physiological processes in eukaryotic cells, the main way for cell lysosomes processing endogenous substrates, including the removal of waste cells, reconstruction of structure and growth life. To maintain the balance of protein metabolism and cell homeostasis, and is closely related with the occurrence of the disease at present. Autophagy, mainly in the form of academic circles have been recognized: macroautophagy (macroautophagy), microautophagy (microautophagy), as well as molecular chaperone mediated autophagy (chaperone mediated, autophagy, CMA). The giant autophagy is that we are often called autophagy. Currently autophagy pathways known: Beclin-1 signaling pathway; mTOR (Mammalian Target of Rapamycin) signaling pathway of autophagy related genes (Autophagy, Related; Gene, Atg) system combined with ubiquitin like (Ubiquitin-link system). Among them, the autophagy gene Beclin-1 and yeast from Phage Atg6 homologous gene, located on chromosome 17q21, forming localized in the Golgi in mammalian autophagy, is a key factor mediated autophagy protein located in the other before the autophagosome. Prostate cancer (Prostate Cancer PCa) is a common malignant tumor in male society. In recent years, the incidence in the male population in China was gradually rising trend. In the treatment of advanced prostate cancer mainly depends on androgen removal methods. However, most patients eventually transformed into androgen resistant prostate cancer (Castrate-Resistant Prostate Cancer, CRPC), resulting in the effect of castration in response to the traditional poor. Studies have proved that autophagy plays an important role in CRPC, and autophagy gene Beclin-1 in various tumor tissues showed low expression indicates that autophagy in prostate carcinogenesis, development, to play a role Expression. The method of immunohistochemical detection of Beclin-1 in prostate cancer tissues and to explore its relationship with clinical and pathological factors. This study used by pathology after transrectal prostate biopsy, a total of 132 cases, all specimens were pathologically confirmed prostate adenocarcinoma in this research. The experimental group is prostate adenocarcinoma, the control group is the benign prostatic hyperplasia. Every case were included in the study were at least one needle for benign prostatic hyperplasia (i.e. carcinoma). With the color of 132 patients with biopsy specimens of all immune groups, if there is any one positive expression that can be put into the corresponding positive group; if all the negative, are included in the negative group. The corresponding expression of Beclin-1 Super Vision two step method for detection of prostate cancer and 132 cases of carcinoma tissues, and analyze the The relationship and clinical factors. The results showed that 1.Beclin-1 positive staining material was brown, expression located in the cytoplasm. In 132 cases of pathological biopsy of the prostate, the positive expression of Beclin-1 in tissue adjacent to carcinoma was 54.5%, the positive expression of Beclin-1 in tumor tissues was 38.6%, was significantly lower than that in the adjacent tissues the expression of.2. in this study, 132 cases of prostate cancer biopsy specimens according to postoperative Gleason score were divided into three groups: 2~4; 5~7; expression of more than 8.Beclin-1 in the three groups in the rates were 66.7%, 39.7%, 27.3%, the higher the score, the expression rate is low, the difference between the groups was statistically difference expression the significance of.3.Beclin-1 and incidence of lymph node metastasis, whether the occurrence of bone metastasis, with statistical significance (P0.05); and whether there is difference with age, medical history and family history of prostatitis were not statistically significant (P0.05.4.) in all 132 Patients with prostate cancer, 76 cases of radical prostatectomy were followed up three months after operation, testing the levels of PSA, 10 cases of more than 0.02ng/ml and 0.02ng/ml. in 66 cases in PSA0.02ng/ml 66 cases in 42 cases of Beclin-1 positive expression, the positive rate was 63.6%, while in PSA over 0.02ng /ml 10 in the cases, 2 cases of positive Beclin-1 expression, the positive rate was 20%, significantly lower than the former (P0.05). These studies suggest that expression of autophagy gene Beclin-1 in prostate cancer with lymph node metastasis and reduction, bone metastasis and biochemical recurrence is related to the down-regulation of its expression may be involved in prostate carcinogenesis, development, provide new ideas for the diagnosis and treatment of prostate cancer.

【學(xué)位授予單位】：安徽醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2015
【分類號(hào)】：R737.25

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 劉運(yùn)初,吳二平,李清,詹炳炎,王玲瓏;前列腺癌組織中轉(zhuǎn)化性生長因子β_2含量的研究[J];同濟(jì)醫(yī)科大學(xué)學(xué)報(bào);2000年02期

2 肖明朝,陳在賢,趙涌,米粲,李圓圓;嗜鉻粒蛋白A在前列腺癌組織中的表達(dá)[J];重慶醫(yī)科大學(xué)學(xué)報(bào);2000年03期

3 葉烈夫,張?jiān)?方祖軍,丁強(qiáng),姚孟樹;前列腺癌組織中Ⅰ型與Ⅱ型5α-還原酶表達(dá)的意義[J];中華醫(yī)學(xué)雜志;2001年24期

4 侯惠蓮,張學(xué)斌,南勛義,張冠軍,王鴻雁,王敏;前列腺癌組織中血管形成的研究[J];西安交通大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2002年03期

5 陳江,陳曉春,曾甫清;腫瘤壞死因子相關(guān)誘導(dǎo)配體受體在前列腺癌組織中的表達(dá)[J];臨床泌尿外科雜志;2003年10期

6 曾浩,魏強(qiáng),石明,張朋,李虹,楊宇如;前列腺特異性抗原表達(dá)與前列腺癌組織學(xué)分級(jí)的相關(guān)性[J];實(shí)用癌癥雜志;2004年01期

7 戚曉平,方麗,林考興,許龍根,閻利,李峰,戴曉紋;整合素連接激酶在前列腺癌組織中的表達(dá)及意義[J];中華男科學(xué)雜志;2005年01期

8 張錫流;何仕遠(yuǎn);張力;楊光業(yè);葉星江;;E-鈣黏附蛋白及其相關(guān)蛋白在前列腺癌組織中的表達(dá)及其臨床意義[J];檢驗(yàn)醫(yī)學(xué);2006年01期

9 畢學(xué)成;何慧嬋;江福能;劉文華;戴奇山;劉良式;魏鴻藹;鐘惟德;;前列腺增生與前列腺癌組織中人腺體激肽釋放酶表達(dá)及臨床意義[J];中華醫(yī)學(xué)雜志;2006年20期

10 譚善峰;;端粒酶在前列腺癌組織中的活性表達(dá)及意義[J];中國醫(yī)藥指南;2007年04期

相關(guān)會(huì)議論文 前10條

1 周曉峰;;泛素降解途徑蛋白在前列腺癌組織中的表達(dá)及臨床意義[A];第十五屆全國泌尿外科學(xué)術(shù)會(huì)議論文集[C];2008年

2 周文泉;印洪林;高建平;張征宇;葛京平;周水根;程文;魏武;馬宏青;馬恒輝;;前列腺癌組織中血管內(nèi)皮生長因子的表達(dá)及其與內(nèi)皮素-1的相關(guān)性研究[A];第十五屆全國泌尿外科學(xué)術(shù)會(huì)議論文集[C];2008年

3 關(guān)明;郭林;張心菊;;定量檢測(cè)前列腺癌組織中肝癌缺失因子1啟動(dòng)子甲基化的高分辨率熔解方法建立及其應(yīng)用意義[A];中華醫(yī)學(xué)會(huì)第八次全國檢驗(yàn)醫(yī)學(xué)學(xué)術(shù)會(huì)議暨中華醫(yī)學(xué)會(huì)檢驗(yàn)分會(huì)成立30周年慶典大會(huì)資料匯編[C];2009年

4 韓雪冰;陳惠慶;宋繼文;米振國;;不同個(gè)體前列腺癌組織培養(yǎng)藥敏試驗(yàn)的研究[A];第十五屆全國泌尿外科學(xué)術(shù)會(huì)議論文集[C];2008年

5 楊磊;單玉喜;陽東榮;;CD44在前列腺癌組織中表達(dá)及臨床意義[A];第十五屆全國泌尿外科學(xué)術(shù)會(huì)議論文集[C];2008年

6 韓兆冬;何慧蟬;戴奇山;鄒鈞;張陽;張征;陳志南;鐘惟德;;CD147 蛋白在前列腺癌組織中特異性表達(dá)的臨床研究[A];第十五屆全國泌尿外科學(xué)術(shù)會(huì)議論文集[C];2008年

7 高新;劉小彭;龐俊;方友強(qiáng);孫其鵬;何丹;蘇祖蘭;;前列腺癌組織CRMP-4基因的檢測(cè)與前列腺癌盆腔淋巴結(jié)早期轉(zhuǎn)移的預(yù)測(cè)[A];第十五屆全國泌尿外科學(xué)術(shù)會(huì)議論文集[C];2008年

8 徐偉;陶志華;王彩虹;翁志梁;胡元平;吳秀玲;李澄棣;陳占國;陳曉東;;實(shí)時(shí)熒光RT-PCR定量檢測(cè)前列腺癌組織中AMACR基因表達(dá)[A];2006年浙江省檢驗(yàn)醫(yī)學(xué)學(xué)術(shù)年會(huì)論文匯編[C];2006年

9 宋濤;洪寶發(fā);高江平;張磊;蔡偉;;前列腺癌組織中凋亡抑制基因Livin表達(dá)的臨床意義[A];中華醫(yī)學(xué)會(huì)第八次全國男科學(xué)學(xué)術(shù)會(huì)議論文集[C];2007年

10 杜穩(wěn)斌;侯建國;武旗;常文軍;張宏偉;曹廣文;;前列腺癌組織中谷胱甘肽S-轉(zhuǎn)移酶P1基因啟動(dòng)子區(qū)域甲基化序列分析[A];第十五屆全國泌尿外科學(xué)術(shù)會(huì)議論文集[C];2008年

相關(guān)博士學(xué)位論文 前3條

1 張慕淳;腫瘤相關(guān)性胰蛋白酶原在前列腺癌組織中的表達(dá)及意義[D];吉林大學(xué);2007年

2 賈萬健;NKX3.1與PTEN在前列腺癌組織表達(dá)及NKX3.1轉(zhuǎn)染PC3細(xì)胞的效應(yīng)[D];復(fù)旦大學(xué);2004年

3 蘇振波;TGF-β1、wt-p53和RhoA基因在人前列腺癌組織中的表達(dá)及其意義[D];吉林大學(xué);2010年

相關(guān)碩士學(xué)位論文 前10條

1 王義昆;ALKBH3和P65在前列腺癌組織中的表達(dá)及意義[D];鄭州大學(xué);2015年

2 徐凌凡;自噬基因Bedin-1在前列腺癌組織中的表達(dá)及意義[D];安徽醫(yī)科大學(xué);2015年

3 陸兵;RAGE和S100A8、S100P在良性前列腺增生和前列腺癌組織中的表達(dá)及臨床意義[D];蘇州大學(xué);2015年

4 康衛(wèi)民;人軟骨糖蛋白-39在前列腺癌組織中的表達(dá)及臨床意義[D];山西醫(yī)科大學(xué);2013年

5 崔傳信;血清PSA的含量與前列腺癌組織學(xué)分級(jí)的相關(guān)性研究[D];吉林大學(xué);2009年

6 喻燕波;前列腺干細(xì)胞抗原和前列腺特異性抗原在前列腺癌組織中的表達(dá)及意義[D];江西醫(yī)學(xué)院;2004年

7 李曉剛;環(huán)氧化酶-2和血管內(nèi)皮細(xì)胞生長因子在前列腺癌組織中的表達(dá)及意義[D];延邊大學(xué);2005年

8 張蔭;胸腺素β、β15在前列腺癌組織中表達(dá)及意義[D];河北大學(xué);2011年

9 楊軼凡;前列腺干細(xì)胞抗原在人前列腺癌組織中的表達(dá)及意義[D];吉林大學(xué);2005年

10 馬寅銳;蛋白酶激活受體和白介素-8在前列腺癌組織中表達(dá)的研究[D];昆明醫(yī)科大學(xué);2014年

，

本文編號(hào)：1651719